Merck Summary


Merck & Co (also known as Merck Sharp & Dohme) is a healthcare manufacturer and distributor of pharmaceuticals. The company operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. Merck offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

HQKenilworth, NJ, USMap
Employee Ratings
Overall CultureBMore


Merck is headquartered in
Kenilworth, United States

Location Map

Latest Updates

Company Growth (employees)

Employees (est.) (Dec 2019)71,000(+3%)
Job Openings3,008
Website Visits (Feb 2021)1 m(+37%)
Revenue (FY, 2020)$48 B(+2%)
Share Price (Apr 2021)$77.1
Cybersecurity ratingAMore

Key People/Management at Merck

Merck Office Locations

Merck has offices in Kenilworth, Albuquerque, Alexandria, Allen and in 253 other locations

Merck Financials and Metrics

Merck Revenue

Merck's revenue was reported to be $47.99 b in FY, 2020


Revenue (FY, 2020)$47.99 b
Gross profit (FY, 2020)$32.51 b
Gross profit margin (FY, 2020), %67.7%
Net income (FY, 2020)$7.08 b
Market capitalization (01-Apr-2021)$195.06 b
Closing stock price(01-Apr-2021)$77.09
Cash (31-Dec-2020)$8.06 b
EV $218.79 b

Merck's current market capitalization is $195.1 b.

USDFY, 2017FY, 2018FY, 2019FY, 2020
Revenue40.1 b42.3 b46.8 b48 b
Revenue growth, %1%5%11%
Cost of goods sold12.8 b13.5 b14.1 b15.5 b
Gross profit27.3 b28.8 b32.7 b32.5 b
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020
Revenue10 b10.5 b10.8 b10.8 b11.8 b12.4 b12.1 b10.9 b12.6 b
Cost of goods sold3.2 b3.4 b3.6 b3.1 b3.4 b4 b3.3 b3.2 b3.5 b
Gross profit6.9 b7 b7.2 b7.8 b8.4 b8.4 b8.7 b7.7 b9.1 b
Gross profit Margin, %68%67%66%72%71%68%73%71%72%
show all

USDFY, 2017FY, 2018FY, 2019FY, 2020
Cash6.1 b8 b9.7 b8.1 b
Accounts Receivable6.9 b7.1 b6.8 b7.9 b
Inventories5.1 b5.4 b6 b6.3 b
Current Assets24.8 b25.9 b27.5 b27.8 b
show all

USDFY, 2017FY, 2018FY, 2019FY, 2020
Net Income2.4 b6.2 b9.8 b7.1 b
Depreciation and Amortization4.6 b4.5 b3.7 b1.9 b
Accounts Receivable297 m(418 m)294 m(1 b)
Inventories(145 m)(911 m)(508 m)(855 m)
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020
Net Income741 m2.5 b4.4 b2.9 b5.5 b7.4 b3.2 b6.2 b9.2 b
Depreciation and Amortization1.1 b2.4 b3.4 b898 m1.9 b2.7 b821 m1.9 b2.7 b
Cash From Operating Activities1.2 b4.5 b7.3 b1.3 b4.4 b8.6 b707 m4.1 b6.2 b
Capital Expenditures(450 m)(1 b)(1.7 b)(595 m)(1.4 b)(2.3 b)(986 m)(1.7 b)(3.2 b)
show all

FY, 2020
EV/CFO22.5 x
Financial Leverage3.6 x
  • Merck Market Cap History

  • Merck Stock Price

Revenue Breakdown

Merck revenue breakdown by business segment: 9.4% from Animal Health, 89.1% from Pharmaceutical and 1.5% from Other

Merck revenue breakdown by geographic segment: 6.3% from Asia Pacific (other than Japan and China), 6.8% from China, 5.3% from Latin America, 27.1% from Europe, Middle East and Africa, 43.4% from United States, 7.6% from Japan and 3.4% from Other

Merck Operating Metrics

Merck's Phase III Trials Products was reported to be 25 in Nov, 2020.

FY, 2015FY, 2016FY, 2017May, 2018Nov, 2018FY, 2018FY, 2019Apr, 2020Aug, 2020Nov, 2020
Drugs Approved by FDA1
Phase III Trials Products241820201724242425
Projects in R&D Pipeline4110

Merck Acquisitions / Subsidiaries

Company NameDateDeal Size
OncoImmuneNovember 23, 2020$425 m
VelosBioNovember 06, 2020$2.75 b
Themis BioscienceMay 26, 2020
ArQuleDecember 09, 2019$2.7 b
Calporta Therapeutics, Inc.November 13, 2019$576 m
Tilos TherapeuticsJune 10, 2019$773 m
Peloton TherapeuticsMay 21, 2019$2.25 b
ConnectMedApril 05, 2019
Immune DesignFebruary 21, 2019$300 m
Antelliq GroupDecember 14, 2018$2.4 b

Human Capital Metrics


Merck Hiring Categories

Merck Median Salaries

Source: 8 public H-1B filings from Merck

Merck Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Merck Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset


out of 100

CSRHub logo

Merck Website Traffic

Alexa Website Rank

Total Visits per monthSimilarWeb

Merck Online and Social Media Presence

Twitter followers

206.7 k Twitter followers

6 Months

Merck has 206.7 k Twitter Followers. The number of followers has increased 1.36% month over month and increased 4.41% quarter over quarter.

Merck's Trends

Search term - Merck

Twitter Engagement Stats for @merck

  • 8.73 k


  • 1 k


  • 206.7 k


  • 51

    Tweets last 30 days

  • 42.9

    Avg. likes per Tweet

  • 100%

    Tweets with engagement

Merck Technology StackBuildWith Logo

  • ads

    2 products used

    • DoubleClick.Net
    • ExactTarget
  • analytics

    7 products used

    • DoubleClick Floodlight
    • Facebook Domain Insights
    • Global Site Tag
      • Google Analytics
      • Google Universal Analytics
      • Tealium UTAG
      • WebTrends
  • cdn

    10 products used

    • AJAX Libraries API
    • Akamai
    • Akamai Global Host
      • CDN JS
      • Cloudflare
      • Cloudflare JS
      • Content Delivery Network
      • jsDelivr
      • OSS CDN
      • WordPress Grid
  • cdns

    1 product used

    • Akamai Edge
Learn more on BuiltWith

Merck Company CultureCultureAndCompensation Logo

  • Overall Culture



  • CEO Rating



  • Compensation



  • Diversity



Learn more on Comparably

Merck News and Updates

Apr 01, 2021
F-star Therapeutics Announces Third Option Exercised by Merck KGaA, Darmstadt, Germany in Immuno-Oncology Collaboration
_3xOCqCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces that Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany has exercised its option to develop an additional bispecific program under the ongoing collaboration with F-star.
Apr 01, 2021
Global Pharmaceuticals Market Report 2021-2030 Featuring Major Players - Pfizer; F. Hoffmann-La Roche Ltd; Sanofi; Johnson & Johnson and Merck & Co
DUBLIN, April 1, 2021 /PRNewswire/ -- The "Pharmaceuticals Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to's offering. Pharmaceuticals Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides the strategists,...
Mar 29, 2021
Samsung Bioepis Continues Global Market Expansion with Launch of HADLIMA™ in Australia and Canada in partnership with Merck & Co.
_3xOCqINCHEON, Korea, March 29, 2021 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced its expansion of its global footprint to Australia with the launch of HADLIMA™ i (adalimumab), a biosimilar referencing HUMIRA ii(adalimumab) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and paediatric Crohn’s disease, ulcerative colitis, hidradenitis suppurativa and plaque psoriasis.
Mar 24, 2021
Merck names Treasurer Caroline Litchfield CFO effective April 1
_3xOCqMerck said Wednesday it has named Caroline Litchfield as its chief financial officer effective April 1, replacing Robert M. Davis, who will become president effective April 1 and chief executive on July 1. Litchfield is currently Merck's treasurer, overseeing treasury, tax and investor relations. The executive joined Merck in 1990 and has held various positions at the company. Merck shares were flat premarket, but are down 6.8% in the year to date, while the S&P 500 has gained 4%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit for more information on this news.
Mar 22, 2021
Merck Stock Remains Significantly Undervalued At $77
_3xOCqMerck looks very attractive at current levels of $77, as it is up only 17% from the levels it was at on March 23, 2020, when broader markets made a bottom due to the spread of Covid-19. This marks a significant underperformance compared to the S&P which has moved 75% since its March 2020 lows...
Mar 19, 2021
Global Membrane Industry to 2025 - Featuring General Electric, Koch Industries & Merck KGaA Among Others
Dublin, March 19, 2021 (GLOBE NEWSWIRE) -- The "Global Membrane Market 2021-2025" report has been added to's offering. The publisher has been monitoring the membrane market and it is poised to grow by $3.65 billion during 2021-2025 progressing at a CAGR of 7% during the forecast period. The report on membrane market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing incidence of diabetes, advantages of membrane technology in pharmaceutical and medical industries, and growing acceptance of wastewater management. The membrane market analysis includes technology segment, application segment and geographical landscapes. This study identifies the growing acceptance of wastewater management as one of the prime reasons driving the membrane market growth during the next few years.The report on membrane market covers the following areas:

Merck Blogs

May 28, 2020
Merck’s KEYTRUDA® (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer
Dateline City: KENILWORTH, N.J. KEYTRUDA Monotherapy Significantly Reduced Risk of Disease Progression or Death by 40% and More Than Doubled Median Progression-Free Survival Versus Chemotherapy KEYNOTE-177 is the First Positive Head-to-Head Phase 3 Trial of a Single-Agent, Anti-PD-1 Therapy Compared to Chemotherapy as First-Line Treatment for Patients with MSI-H Colorectal Cancer KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from KEYNOTE-177, a Phase 3 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for the first-line treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer. Language: English Contact: Media Contacts: Pamela Eisele (267) 305-3558 Justine Moore (908) 740-6449 Investor Contacts: Peter Dannenbaum (908) 740-1037 Courtney Ronaldo (908) 740-6132 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
May 26, 2020
Merck Announces Third-Quarter 2020 Dividend
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.61 per share of the company’s common stock for the second quarter of 2020. Payment will be made on July 7, 2020 to shareholders of record at the close of business on June 15, 2020. About Merck Language: English Contact: Media: Pamela Eisele (267) 305-3558 Investor: Peter Dannenbaum (908) 740-1037 Michael DeCarbo (908) 740-1807 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
May 26, 2020
Merck to Acquire Themis
Dateline City: KENILWORTH, N.J. Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine Program Originated by Themis and Institut Pasteur KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Themis, a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire privately-held Themis. Language: English Contact: Merck Media: Patrick Ryan +1 (201) 452-2409 Ian McConnell +1 (973) 901-5722 Themis Media & Investors Gretchen Schweitzer +49 172 861 8540 Jacob Verghese +49 89 2388 7731 Merck Investors: Peter Dannenbaum +1 (908) 740-1037 Michael DeCarbo +1 (908) 740-1807 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
May 20, 2020
LYNPARZA® (olaparib) Approved by FDA for Treatment of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone
Dateline City: KENILWORTH, N.J. Only PARP Inhibitor to Improve Overall Survival vs. Enzalutamide or Abiraterone for Metastatic Castration-Resistant Prostate Cancer Patients with BRCA or ATM Mutations, A Key Secondary Endpoint in the Phase 3 PROfound Trial Approximately 20-30% of Men with Metastatic Castration-Resistant Prostate Cancer Have an HRR Gene Mutation KENILWORTH, N.J.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved LYNPARZA for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Patients will be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Language: English Contact: Media Contacts: Pamela Eisele (267) 305-3558 Steve Wanczyk (267) 305-5563 Investor Contacts: Peter Dannenbaum (908) 740-1037 Courtney Ronaldo (908) 740-6132 Ticker Slug: Ticker: MRK Exchange: NYSE Organization,Facebook,Merck @Merck read more
May 19, 2020
Infectious Disease Connect and ILÚM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship
Dateline City: KENILWORTH, N.J. & PITTSBURGH Agreement Includes Strategic Investments from UPMC Enterprises and Merck Global Health Innovation Fund KENILWORTH, N.J. & PITTSBURGH--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and UPMC today announced that Infectious Disease Connect Inc., a UPMC-backed company offering telemedicine-enabled solutions to hospitals for treatment of infectious diseases, has combined with Merck’s ILÚM Health Solutions, a provider of technology and services to support infectious disease management, clinical decision-support and precision antibiotic therapy. Language: English Contact: UPMC Contact: Courtney Caprara Office: 412-647-6190 Mobile: 412-592-8134 E-mail: UPMC Contact: Wendy Zellner Office: 412-586-9777 Mobile: 412-973-7266 Email: Merck Media Contact: Pamela Eisele 267-305-3558 Merck Investor Relations Contact: Peter Dannenbaum 908-740-1037 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
May 18, 2020
Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Matthew Walsh and Rachel Stahler as Chief Financial Officer and Chief Information Officer, respectively, for Organon & Co., its intended spinoff of its women’s health, legacy brands and biosimilars businesses. Language: English Contact: Media: Jessica Fine (908) 740-1707 Kate Vossen (732) 675-8448 Investor: Peter Dannenbaum (908) 740-1037 Michael DeCarbo (908) 740-1807 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more

You may also be interested in Related companies

Cambridge, US
SynDevRx is a company dedicated to developing treatments for patients whose cancer is associated with metabolic dysfunction.
View company
NED Biosystems
Cambridge, US
NED Biosystems is a clinical-stage company developing cancer treatments as well as HIV/AIDS and diabetes treatments.
View company
Alteogen is a biopharmaceutical company that develops therapeutic proteins, antibody-drug conjugates, (ADC), and monoclonal antibody biosimilars.
View company
Applied Therapeutics
New York, US
11  10increase
Applied Therapeutics is a clinical-stage biopharmaceutical company developing therapies for diabetic complications.
View company
When was Merck founded?
Merck was founded in 1891.
Who are Merck key executives?
Merck's key executives are Kenneth Frazier, Sanat Chattopadhyay and Frank Clyburn.
How many employees does Merck have?
Merck has 71,000 employees.
What is Merck revenue?
Latest Merck annual revenue is $47.99 b.
What is Merck revenue per employee?
Latest Merck revenue per employee is $659.72 k.
Who are Merck competitors?
Competitors of Merck include Bausch Health, Sanofi and Zoetis.
Where is Merck headquarters?
Merck headquarters is located at 2000 Galloping Hill Rd, Kenilworth.
Where are Merck offices?
Merck has offices in Kenilworth, Albuquerque, Alexandria, Allen and 254 other locations
How many offices does Merck have?
Merck has 266 offices.

Craft real-time company insights

Learn about Craft real-time company insights

Receive alerts for 300+ data fields across thousands of companies

Footer menu